|
WO2007012133A1
|
|
Therapeutic protocols using hyaluronan
|
|
WO2005016386A1
|
|
Improved therapeutic protocols
|
|
AU2003903391A0
|
|
Therapeutic agents and uses therefor
|
|
AU2002952657A0
|
|
Therapeutic agents and uses therefor-II
|
|
CA2458856A1
|
|
Improved therapeutic protocols
|
|
AUPS271802A0
|
|
Therapeutic agents and uses therefor
|
|
AUPS116402A0
|
|
An assay
|
|
AUPR950401A0
|
|
Methods for treatment
|
|
AUPR730201A0
|
|
Preventive treatment for toxic side-effects caused by chemotherapeutic agents
|
|
AUPR694701A0
|
|
Heterogenous assay methods and means
|
|
AU7220201A
|
|
Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
|
|
ZA200105492B
|
|
A composition and method for the enhancement of the efficacy of drugs.
|
|
AUPQ879500A0
|
|
Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
|
|
AUPQ508500A0
|
|
Chemotherapeutic compostion for the tretment of disease
|
|
AU2423100A
|
|
A composition and method for the enhancement of the efficacy of drugs
|
|
NZ512676A
|
|
A composition and method for the enhancement of the efficacy of drugs
|
|
AUPQ393899A0
|
|
A composition and method for the enhancement of the efficacy of drugs
|
|
NZ320006A
|
|
An adjuvant composition comprising hyaluronic acid for gene therapy either in the sense or antisense direction
|
|
AU7266496A
|
|
Hyaluronic acid as DNA carrier for gene therapy and VEGF antisense DNA to treat abnormal retinal vascularization
|
